Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy
- PMID: 22156007
- DOI: 10.1258/ar.2011.110273
Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy
Abstract
Background: Tumor response to chemotherapy has traditionally been assessed by using Response Evaluation Criteria in Solid Tumors (RECIST) based on changes in tumor size alone. However, adapted Choi criteria, which incorporate volumetric tumor attenuation in addition to tumor size, have been reported more predictive of chemotherapeutic efficacy than RECIST in some studies.
Purpose: To examine the usefulness of adapted Choi criteria in predicting clinical survival in locally advanced gastric cancer patients treated with cytotoxic drugs.
Material and methods: A total of 48 histologically proven gastric cancer patients who received neoadjuvant chemotherapy and surgery were involved. Pre- and post-chemotherapy short-axis diameter and volumetric mean tumor attenuation of target lymph nodes on contrast-enhanced CT images were measured. Tumor response was assessed by using both RECIST and adapted Choi criteria, and was correlated with progression-free survival (PFS) and overall survival (OS).
Results: Significant decrease was observed in the sum of short-axis diameters and tumor attenuation of metastatic lymph nodes between baseline and post-chemotherapy CT images. The inter-observer agreement for both parameters was good. The PFS and OS of 17 RECIST responders were identical with that of 28 adapted Choi responders (P = 0.855 and 0.913, respectively). PFS and OS of 31 RECIST non-responders were significantly prolonged compared to that of 20 adapted Choi non-responders (P = 0.018 and 0.042, respectively). To the 11 RECIST stable disease (SD) but adapted Choi partial response (PR) patients, the PFS and OS were similar to the survival of 17 RECIST PR patients (P = 0.785 and 0.838, respectively), but significantly prolonged compared to that of the 12 both RECIST and adapted Choi criteria SD patients (P < 0.001 and P = 0.004, respectively).
Conclusion: Adapted Choi criteria might be helpful to predict PFS and OS in locally advanced gastric cancer patients following chemotherapy.
Similar articles
-
[Value of dual-energy CT-based volumetric iodine-uptake in the evaluation of chemotherapy efficacy in advanced gastric cancer].Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Oct 25;22(10):977-983. doi: 10.3760/cma.j.issn.1671-0274.2019.10.014. Zhonghua Wei Chang Wai Ke Za Zhi. 2019. PMID: 31630497 Chinese.
-
Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria.Eur J Radiol. 2013 Jun;82(6):951-8. doi: 10.1016/j.ejrad.2013.02.034. Epub 2013 Mar 19. Eur J Radiol. 2013. PMID: 23518148 Clinical Trial.
-
Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?BMC Cancer. 2017 Feb 23;17(1):154. doi: 10.1186/s12885-017-3150-7. BMC Cancer. 2017. PMID: 28231773 Free PMC article.
-
Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer.World J Gastroenterol. 2014 Feb 21;20(7):1650-6. doi: 10.3748/wjg.v20.i7.1650. World J Gastroenterol. 2014. PMID: 24587644 Free PMC article. Review.
-
Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review.Cancer Chemother Pharmacol. 2017 Oct;80(4):729-735. doi: 10.1007/s00280-017-3411-9. Epub 2017 Aug 5. Cancer Chemother Pharmacol. 2017. PMID: 28780726 Review.
Cited by
-
Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study.Gastroenterol Res Pract. 2018 Mar 15;2018:1794524. doi: 10.1155/2018/1794524. eCollection 2018. Gastroenterol Res Pract. 2018. PMID: 29736166 Free PMC article.
-
Intratumoral and peritumoral radiomics predict pathological response after neoadjuvant chemotherapy against advanced gastric cancer.Insights Imaging. 2024 Jan 25;15(1):23. doi: 10.1186/s13244-023-01584-6. Insights Imaging. 2024. PMID: 38270724 Free PMC article.
-
mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response.Eur Radiol. 2016 Jan;26(1):278-85. doi: 10.1007/s00330-015-3828-7. Epub 2015 May 8. Eur Radiol. 2016. PMID: 25953002 Clinical Trial.
-
Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer-a multicenter study of GIRCG (Italian Research Group for Gastric Cancer).Quant Imaging Med Surg. 2021 Jun;11(6):2376-2387. doi: 10.21037/qims-20-683. Quant Imaging Med Surg. 2021. PMID: 34079708 Free PMC article.
-
A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.Gastric Cancer. 2016 Apr;19(2):586-596. doi: 10.1007/s10120-015-0490-3. Epub 2015 Apr 8. Gastric Cancer. 2016. PMID: 25851942 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials